ARS PHARMACEUTICALS, INC.
| Revenue | $116.9M |
|---|---|
| Operating income | $-121.6M |
| Net income | $-123.0M |
| Free cash flow | $-105.9M |
| Operating margin | -104.0% |
| Net margin | -105.2% |
| Return on equity | -982.7% |
| Period | TTM 2026-06-30 |
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
high-risk execution story, not yet a clear buy.
Neffy momentum is encouraging—Q2 net product revenue was $26.2 million, U.S. market share reached 5% versus 2.5% a year ago, and targeted-account share reached 8%—but the commercial model remains unproven outside the field-force universe. The planned >40% cash SG&A reduction supports management’s end-2027 cash-flow-breakeven target, yet 62% gross margin, gross-to-net approaching 50%, a $62.3 million net loss, and limited quantified revenue assumptions leave substantial execution and funding risk.
Near term
Q3 back-to-school season should provide a volume tailwind, but management expects gradual provider-by-provider share gains rather than a sharp acceleration.
The fully deployed sales force and new Chief Commercial Officer are the main near-term catalysts; the key validation will be whether targeted-account share rises above 8% and whether the 1% share in non-targeted areas improves indirectly.
Second-half cash-based SG&A and R&D spending is expected to fall to $100 million-$110 million, which may improve sentiment if quarterly revenue remains resilient.
Payer access is relatively strong at 90% commercial coverage, but only 57% of Medicaid coverage requires no prior authorization; management emphasized that provider conviction, not coverage alone, is the primary bottleneck.
Longer term
The core thesis depends on converting neffy from an alternative to entrenched auto-injector prescribing habits. Repeated field engagement has produced an 8% versus approximately 1% share differential, but management has not demonstrated that this gap reflects a durable, scalable causal advantage.
The end-2027 cash-flow-breakeven target relies on continued expense discipline and unspecified revenue and market-share gains. Sustained revenue growth will be necessary because Q2 total operating expenses were $95.1 million against $33.7 million of total revenue.
The CSU Phase 2b program could expand the intranasal epinephrine platform and leverage the existing commercial infrastructure, but the interim readout has moved to Q1 2027 and remains an important binary pipeline catalyst.
Manufacturing scale-up and ex-U.S. launches could improve margins over time, but the current economics are materially weaker than the long-term narrative suggests.
Red flags
Gross margin was only 62% in Q2 because of short-dated inventory reserves, manufacturing inefficiencies, and ex-U.S. launch costs; management gave no quantified margin target or timetable beyond general improvement into 2027.
Gross-to-net is approaching 50% and may fluctuate with mix, creating a substantial gap between gross demand and reported revenue and making prescription growth harder to translate into economics.
The 8% targeted-universe share versus approximately 1% in non-targeted areas is encouraging but may reflect account selection and is not proof that the commercial model scales across the broader 56% of market opportunity outside the targeted universe.
Management cited confidence in cash-flow breakeven but did not quantify the revenue, market-share, gross-margin, or reimbursement assumptions supporting the target. With $143.8 million of cash and projected second-half cash-based operating expenses of $100 million-$110 million, execution timing matters.
The CSU interim readout delay to Q1 2027 extends pipeline uncertainty and pushes out a potential valuation catalyst.
The July intellectual-property license was described only as a possible line-extension opportunity, with no disclosed development plan, economics, or expected timing.
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
From latest 10-K · 2026-03-09
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
Red flags
- Sbc Revenue High — SBC/Revenue 26.2%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -203.3%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -202.7%
- Cash Runway Low — Cash runway ~0.2 years
- Accumulated Deficit High — Accumulated deficit / equity 258%
Upcoming earnings
Earnings transcripts
Press & signals
- GlobeNewswire
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results